Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Teladoc Health, Inc.TDOC · Entity 1547 | Director | May 21, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Teladoc Health, Inc.
Report date May 21, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 30,441 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 30,441 · Balance 30,441 F1: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2: The restricted stock units vest in full on the earlier of (i) May 21, 2027 and (ii) the day immediately preceding the issuer's 2027 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.
F2: The restricted stock units vest in full on the earlier of (i) May 21, 2027 and (ii) the day immediately preceding the issuer's 2027 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Livongo Health, Inc.
Report date October 30, 2020 · Filed October 30, 2020
Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 1
1 source rowRow 1 · 2020-10-30 · Disposition to issuer · Disposed 79,142 · Balance 0 F1: Includes 31,232 restricted stock units ("RSUs"). F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F3: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 31,232 restricted stock units ("RSUs").
F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).
F3: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).
F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 21, 2026 21:13 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GrantRestricted Stock Units · Derivative | 30,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001302954-26-000002 · wk-form4_1779398027.xml · derivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,441 Underlying: Common Stock · 30,441 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the earlier of (i) May 21, 2027 and (ii) the day immediately preceding the issuer's 2027 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. F2 · derivative.expiration_date: The restricted stock units vest in full on the earlier of (i) May 21, 2027 and (ii) the day immediately preceding the issuer's 2027 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:05 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GrantRestricted Stock Units · Derivative | 28,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001477449-25-000064 · wk-form4_1748030737.xml · derivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,986 Underlying: Common Stock · 28,986 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the earlier of (i) May 22, 2026 and (ii) the day immediately preceding the issuer's 2026 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. F2 · derivative.expiration_date: The restricted stock units vest in full on the earlier of (i) May 22, 2026 and (ii) the day immediately preceding the issuer's 2026 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:27 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GrantRestricted Stock Units · Derivative | 17,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001477449-24-000127 · wk-form4_1716582417.xml · derivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,467 Underlying: Common Stock · 17,467 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the earlier of (i) May 23, 2025 and (ii) the day immediately preceding the issuer's 2025 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. F2 · derivative.expiration_date: The restricted stock units vest in full on the earlier of (i) May 23, 2025 and (ii) the day immediately preceding the issuer's 2025 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. Read SEC document |
| November 17, 2023 Filed Nov 20, 2023 21:05 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 436 | $0.00 | $0.00 |
DisclosureSEC source: 0001477449-23-000081 · wk-form4_1700514303.xml · derivative · entry 3 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 436 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F4 · derivative.exercise_date: The restricted stock units vest in three substantially equal annual installments beginning November 19, 2021. F4 · derivative.expiration_date: The restricted stock units vest in three substantially equal annual installments beginning November 19, 2021. Read SEC document |
| November 17, 2023 Filed Nov 20, 2023 21:05 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 436 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477449-23-000081 · wk-form4_1700514303.xml · nonDerivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:22 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GrantRestricted Stock Units · Derivative | 9,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-008844 · form4-05262023_080522.xml · derivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,834 Underlying: Common Stock · 9,834 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the earlier of (i) May 25, 2024 and (ii) the day immediately preceding the issuer's 2024 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. F2 · derivative.expiration_date: The restricted stock units vest in full on the earlier of (i) May 25, 2024 and (ii) the day immediately preceding the issuer's 2024 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 21:09 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 436 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-011626 · form4-11212022_091136.xml · derivative · entry 3 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436 Underlying: Common Stock · 436 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F4 · derivative.exercise_date: The restricted stock units vest in three substantially equal annual installments beginning November 19, 2021. F4 · derivative.expiration_date: The restricted stock units vest in three substantially equal annual installments beginning November 19, 2021. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 21:09 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 436 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-011626 · form4-11212022_091136.xml · nonDerivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| May 26, 2022 Filed May 31, 2022 20:22 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GrantRestricted Stock Units · Derivative | 6,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-005901 · form4-05312022_010522.xml · derivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,726 Underlying: Common Stock · 6,726 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the earlier of (i) May 26, 2023 and (ii) the day immediately preceding the issuer's 2023 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. F2 · derivative.expiration_date: The restricted stock units vest in full on the earlier of (i) May 26, 2023 and (ii) the day immediately preceding the issuer's 2023 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 436 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005435 · form4-11232021_011130.xml · derivative · entry 3 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 872 Underlying: Common Stock · 436 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F4 · derivative.exercise_date: The restricted stock unit vests in three substantially equal annual installments beginning November 19, 2021. F4 · derivative.expiration_date: The restricted stock unit vests in three substantially equal annual installments beginning November 19, 2021. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 436 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-21-005435 · form4-11232021_011130.xml · nonDerivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 3,587 | $140.00 | $502,180.00 |
DisclosureSEC source: 0001179110-21-009441 · edgar.xml · nonDerivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,762 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on September 14, 2021. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | SaleCommon Stock | 7,173 | $164.63 | $1,180,890.99 |
DisclosureSEC source: 0001179110-21-007428 · edgar.xml · nonDerivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,349 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on June 3, 2021. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 715 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005966 · edgar.xml · derivative · entry 4 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F3 · derivative.exercise_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. F3 · derivative.expiration_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 6,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005966 · edgar.xml · derivative · entry 3 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,461 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F3 · derivative.exercise_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. F3 · derivative.expiration_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:10 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 7,176 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-005966 · edgar.xml · nonDerivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| May 17, 2021 Filed May 18, 2021 20:14 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GrantRestricted Stock Units · Derivative | 1,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005483 · edgar.xml · derivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,638 Underlying: Common Stock · 1,638 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the earlier of (i) May 17, 2022 and (ii) the day immediately preceding the issuer's 2022 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. F2 · derivative.expiration_date: The restricted stock units vest in full on the earlier of (i) May 17, 2022 and (ii) the day immediately preceding the issuer's 2022 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:40 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 713 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002341 · edgar.xml · derivative · entry 4 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 715 Underlying: Common Stock · 713 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F3 · derivative.exercise_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. F3 · derivative.expiration_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:40 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 6,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002341 · edgar.xml · derivative · entry 3 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,461 Underlying: Common Stock · 6,460 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F3 · derivative.exercise_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. F3 · derivative.expiration_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:40 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 7,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-002341 · edgar.xml · nonDerivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| December 29, 2020 Filed Feb 10, 2021 21:00 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GiftCommon Stock | 28,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001505 · edgar.xml · nonDerivative · entry 2 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Geoffrey L. Fenwick Family Irrevocable Trust dated 12/17/2020 Disclosed balance after: 28,362 F1 · ownership.nature: The shares are held of record by the Geoffrey L. Fenwick Family Irrevocable Trust for the benefit of the reporting person's children and for which the reporting person and her spouse serve as co-trustees. Read SEC document |
| December 29, 2020 Filed Feb 10, 2021 21:00 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GiftCommon Stock | 28,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001505 · edgar.xml · nonDerivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,173 Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 21:04 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 713 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011460 · edgar.xml · derivative · entry 3 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 Underlying: Common Stock · 713 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F3 · derivative.exercise_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. F3 · derivative.expiration_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 21:04 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 6,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011460 · edgar.xml · derivative · entry 2 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,921 Underlying: Common Stock · 6,460 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F3 · derivative.exercise_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. F3 · derivative.expiration_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 21:04 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 7,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-011460 · edgar.xml · nonDerivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 21:43 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GrantRestricted Stock Units · Derivative | 1,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011268 · edgar.xml · derivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,308 Underlying: Common Stock · 1,308 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2 · derivative.exercise_date: The restricted stock unit vests in three substantially equal annual installments beginning November 19, 2021. F2 · derivative.expiration_date: The restricted stock unit vests in three substantially equal annual installments beginning November 19, 2021. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 21:27 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerCommon Stock | 79,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001639225-20-000067 · wf-form4_160409321355278.xml · nonDerivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 31,232 restricted stock units ("RSUs"). F2 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F3 · price: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F4 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. Read SEC document |
| May 19, 2020 Filed May 29, 2020 22:36 UTC | Livongo Health, Inc. LVGO · Entity 145566 | GrantCommon Stock | 4,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-033045 · doc4.xml · nonDerivative · entry 1 Fenwick Sandra L · CIK 0001302954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,142 F1 · shares: The reported shares are represented by restricted stock units which vest in four equal quarterly installments beginning on August 25, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.